 | • レポートコード：MRC2Q12-18939 • 出版社/出版日：QYResearch / 2022年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥744,800 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,489,600 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、注射用絨毛性ゴナドトロピンのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 注射用絨毛性ゴナドトロピンのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 注射用絨毛性ゴナドトロピンの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 注射用絨毛性ゴナドトロピンのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの注射用絨毛性ゴナドトロピンの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の注射用絨毛性ゴナドトロピンの売上および2028年までの予測に焦点を当てています。 注射用絨毛性ゴナドトロピンのグローバル主要企業には、Beijing Science Sun Pharmaceutical、Shenyang EverBright Pharmaceutical、Yantai Dongcheng Beifang Pharmaceutical、Livzon Pharmaceutical Group、Ningbo Renjian Pharmaceutical、Ma'anshan Fengyuan Pharmaceutical、Harbin High-Tech Group Baitian'er Pharmaceutical、Sinopharm、Besins Healthcare Benelux、Bristol Myers Squibb、Organonなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 注射用絨毛性ゴナドトロピン市場は、タイプとアプリケーションによって区分されます。世界の注射用絨毛性ゴナドトロピン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 1000U/個、2000U/個、5000U/個 【アプリケーション別セグメント】 病院薬局、小売薬局、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 注射用絨毛性ゴナドトロピン製品概要 - タイプ別市場（1000U/個、2000U/個、5000U/個） - アプリケーション別市場（病院薬局、小売薬局、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の注射用絨毛性ゴナドトロピン販売量予測2017-2028 - 世界の注射用絨毛性ゴナドトロピン売上予測2017-2028 - 注射用絨毛性ゴナドトロピンの地域別販売量 - 注射用絨毛性ゴナドトロピンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別注射用絨毛性ゴナドトロピン販売量 - 主要メーカー別注射用絨毛性ゴナドトロピン売上 - 主要メーカー別注射用絨毛性ゴナドトロピン価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（1000U/個、2000U/個、5000U/個） - 注射用絨毛性ゴナドトロピンのタイプ別販売量 - 注射用絨毛性ゴナドトロピンのタイプ別売上 - 注射用絨毛性ゴナドトロピンのタイプ別価格 ・アプリケーション別市場規模（病院薬局、小売薬局、その他） - 注射用絨毛性ゴナドトロピンのアプリケーション別販売量 - 注射用絨毛性ゴナドトロピンのアプリケーション別売上 - 注射用絨毛性ゴナドトロピンのアプリケーション別価格 ・北米市場 - 北米の注射用絨毛性ゴナドトロピン市場規模（タイプ別、アプリケーション別） - 主要国別の注射用絨毛性ゴナドトロピン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの注射用絨毛性ゴナドトロピン市場規模（タイプ別、アプリケーション別） - 主要国別の注射用絨毛性ゴナドトロピン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の注射用絨毛性ゴナドトロピン市場規模（タイプ別、アプリケーション別） - 主要国別の注射用絨毛性ゴナドトロピン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の注射用絨毛性ゴナドトロピン市場規模（タイプ別、アプリケーション別） - 主要国別の注射用絨毛性ゴナドトロピン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの注射用絨毛性ゴナドトロピン市場規模（タイプ別、アプリケーション別） - 主要国別の注射用絨毛性ゴナドトロピン市場規模（トルコ、サウジアラビア） ・企業情報 Beijing Science Sun Pharmaceutical、Shenyang EverBright Pharmaceutical、Yantai Dongcheng Beifang Pharmaceutical、Livzon Pharmaceutical Group、Ningbo Renjian Pharmaceutical、Ma'anshan Fengyuan Pharmaceutical、Harbin High-Tech Group Baitian'er Pharmaceutical、Sinopharm、Besins Healthcare Benelux、Bristol Myers Squibb、Organon ・産業チェーン及び販売チャネル分析 - 注射用絨毛性ゴナドトロピンの産業チェーン分析 - 注射用絨毛性ゴナドトロピンの原材料 - 注射用絨毛性ゴナドトロピンの生産プロセス - 注射用絨毛性ゴナドトロピンの販売及びマーケティング - 注射用絨毛性ゴナドトロピンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 注射用絨毛性ゴナドトロピンの産業動向 - 注射用絨毛性ゴナドトロピンのマーケットドライバー - 注射用絨毛性ゴナドトロピンの課題 - 注射用絨毛性ゴナドトロピンの阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Chorionic Gonadotrophin for Injection is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Chorionic Gonadotrophin for Injection is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Chorionic Gonadotrophin for Injection is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Chorionic Gonadotrophin for Injection include Beijing Science Sun Pharmaceutical, Shenyang EverBright Pharmaceutical, Yantai Dongcheng Beifang Pharmaceutical, Livzon Pharmaceutical Group, Ningbo Renjian Pharmaceutical, Ma’anshan Fengyuan Pharmaceutical, Harbin High-Tech Group Baitian’er Pharmaceutical, Sinopharm and Besins Healthcare Benelux, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chorionic Gonadotrophin for Injection manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Chorionic Gonadotrophin for Injection market. Further, it explains the major drivers and regional dynamics of the global Chorionic Gonadotrophin for Injection market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Beijing Science Sun Pharmaceutical
Shenyang EverBright Pharmaceutical
Yantai Dongcheng Beifang Pharmaceutical
Livzon Pharmaceutical Group
Ningbo Renjian Pharmaceutical
Ma’anshan Fengyuan Pharmaceutical
Harbin High-Tech Group Baitian’er Pharmaceutical
Sinopharm
Besins Healthcare Benelux
Bristol Myers Squibb
Organon
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by specification and by application segments based on sales, price, and value for the period 2017-2028.
Chorionic Gonadotrophin for Injection Segment by Specification
1000U/Piece
2000U/Piece
5000U/Piece
Chorionic Gonadotrophin for Injection Segment by Application
Hospital Pharmacy
Retail Pharmacy
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Chorionic Gonadotrophin for Injection market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Chorionic Gonadotrophin for Injection, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Chorionic Gonadotrophin for Injection, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Chorionic Gonadotrophin for Injection, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Chorionic Gonadotrophin for Injection sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Chorionic Gonadotrophin for Injection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Chorionic Gonadotrophin for Injection sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Beijing Science Sun Pharmaceutical, Shenyang EverBright Pharmaceutical, Yantai Dongcheng Beifang Pharmaceutical, Livzon Pharmaceutical Group, Ningbo Renjian Pharmaceutical, Ma’anshan Fengyuan Pharmaceutical, Harbin High-Tech Group Baitian’er Pharmaceutical, Sinopharm and Besins Healthcare Benelux, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Chorionic Gonadotrophin for Injection in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Chorionic Gonadotrophin for Injection manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by specification, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by specification, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by specification, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by specification, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by specification, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chorionic Gonadotrophin for Injection sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Chorionic Gonadotrophin for Injection Product Introduction
1.2 Market by Specification
1.2.1 Global Chorionic Gonadotrophin for Injection Market Size Growth Rate by Specification, 2017 VS 2021 VS 2028
1.2.2 1000U/Piece
1.2.3 2000U/Piece
1.2.4 5000U/Piece
1.3 Market by Application
1.3.1 Global Chorionic Gonadotrophin for Injection Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Chorionic Gonadotrophin for Injection Sales Estimates and Forecasts 2017-2028
2.2 Global Chorionic Gonadotrophin for Injection Revenue Estimates and Forecasts 2017-2028
2.3 Global Chorionic Gonadotrophin for Injection Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Chorionic Gonadotrophin for Injection Sales by Region
2.4.1 Global Chorionic Gonadotrophin for Injection Sales by Region (2017-2022)
2.4.2 Global Sales Chorionic Gonadotrophin for Injection by Region (2023-2028)
2.5 Global Chorionic Gonadotrophin for Injection Revenue by Region
2.5.1 Global Chorionic Gonadotrophin for Injection Revenue by Region (2017-2022)
2.5.2 Global Chorionic Gonadotrophin for Injection Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Chorionic Gonadotrophin for Injection Sales by Manufacturers
3.1.1 Global Top Chorionic Gonadotrophin for Injection Manufacturers by Sales (2017-2022)
3.1.2 Global Chorionic Gonadotrophin for Injection Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Chorionic Gonadotrophin for Injection in 2021
3.2 Global Chorionic Gonadotrophin for Injection Revenue by Manufacturers
3.2.1 Global Chorionic Gonadotrophin for Injection Revenue by Manufacturers (2017-2022)
3.2.2 Global Chorionic Gonadotrophin for Injection Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Chorionic Gonadotrophin for Injection Revenue in 2021
3.3 Global Chorionic Gonadotrophin for Injection Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Chorionic Gonadotrophin for Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Chorionic Gonadotrophin for Injection Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Specification
4.1 Global Chorionic Gonadotrophin for Injection Sales by Specification
4.1.1 Global Chorionic Gonadotrophin for Injection Historical Sales by Specification (2017-2022)
4.1.2 Global Chorionic Gonadotrophin for Injection Forecasted Sales by Specification (2023-2028)
4.1.3 Global Chorionic Gonadotrophin for Injection Sales Market Share by Specification (2017-2028)
4.2 Global Chorionic Gonadotrophin for Injection Revenue by Specification
4.2.1 Global Chorionic Gonadotrophin for Injection Historical Revenue by Specification (2017-2022)
4.2.2 Global Chorionic Gonadotrophin for Injection Forecasted Revenue by Specification (2023-2028)
4.2.3 Global Chorionic Gonadotrophin for Injection Revenue Market Share by Specification (2017-2028)
4.3 Global Chorionic Gonadotrophin for Injection Price by Specification
4.3.1 Global Chorionic Gonadotrophin for Injection Price by Specification (2017-2022)
4.3.2 Global Chorionic Gonadotrophin for Injection Price Forecast by Specification (2023-2028)
5 Market Size by Application
5.1 Global Chorionic Gonadotrophin for Injection Sales by Application
5.1.1 Global Chorionic Gonadotrophin for Injection Historical Sales by Application (2017-2022)
5.1.2 Global Chorionic Gonadotrophin for Injection Forecasted Sales by Application (2023-2028)
5.1.3 Global Chorionic Gonadotrophin for Injection Sales Market Share by Application (2017-2028)
5.2 Global Chorionic Gonadotrophin for Injection Revenue by Application
5.2.1 Global Chorionic Gonadotrophin for Injection Historical Revenue by Application (2017-2022)
5.2.2 Global Chorionic Gonadotrophin for Injection Forecasted Revenue by Application (2023-2028)
5.2.3 Global Chorionic Gonadotrophin for Injection Revenue Market Share by Application (2017-2028)
5.3 Global Chorionic Gonadotrophin for Injection Price by Application
5.3.1 Global Chorionic Gonadotrophin for Injection Price by Application (2017-2022)
5.3.2 Global Chorionic Gonadotrophin for Injection Price Forecast by Application (2023-2028)
6 North America
6.1 North America Chorionic Gonadotrophin for Injection Market Size by Specification
6.1.1 North America Chorionic Gonadotrophin for Injection Sales by Specification (2017-2028)
6.1.2 North America Chorionic Gonadotrophin for Injection Revenue by Specification (2017-2028)
6.2 North America Chorionic Gonadotrophin for Injection Market Size by Application
6.2.1 North America Chorionic Gonadotrophin for Injection Sales by Application (2017-2028)
6.2.2 North America Chorionic Gonadotrophin for Injection Revenue by Application (2017-2028)
6.3 North America Chorionic Gonadotrophin for Injection Market Size by Country
6.3.1 North America Chorionic Gonadotrophin for Injection Sales by Country (2017-2028)
6.3.2 North America Chorionic Gonadotrophin for Injection Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Chorionic Gonadotrophin for Injection Market Size by Specification
7.1.1 Europe Chorionic Gonadotrophin for Injection Sales by Specification (2017-2028)
7.1.2 Europe Chorionic Gonadotrophin for Injection Revenue by Specification (2017-2028)
7.2 Europe Chorionic Gonadotrophin for Injection Market Size by Application
7.2.1 Europe Chorionic Gonadotrophin for Injection Sales by Application (2017-2028)
7.2.2 Europe Chorionic Gonadotrophin for Injection Revenue by Application (2017-2028)
7.3 Europe Chorionic Gonadotrophin for Injection Market Size by Country
7.3.1 Europe Chorionic Gonadotrophin for Injection Sales by Country (2017-2028)
7.3.2 Europe Chorionic Gonadotrophin for Injection Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Chorionic Gonadotrophin for Injection Market Size by Specification
8.1.1 Asia Pacific Chorionic Gonadotrophin for Injection Sales by Specification (2017-2028)
8.1.2 Asia Pacific Chorionic Gonadotrophin for Injection Revenue by Specification (2017-2028)
8.2 Asia Pacific Chorionic Gonadotrophin for Injection Market Size by Application
8.2.1 Asia Pacific Chorionic Gonadotrophin for Injection Sales by Application (2017-2028)
8.2.2 Asia Pacific Chorionic Gonadotrophin for Injection Revenue by Application (2017-2028)
8.3 Asia Pacific Chorionic Gonadotrophin for Injection Market Size by Region
8.3.1 Asia Pacific Chorionic Gonadotrophin for Injection Sales by Region (2017-2028)
8.3.2 Asia Pacific Chorionic Gonadotrophin for Injection Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Chorionic Gonadotrophin for Injection Market Size by Specification
9.1.1 Latin America Chorionic Gonadotrophin for Injection Sales by Specification (2017-2028)
9.1.2 Latin America Chorionic Gonadotrophin for Injection Revenue by Specification (2017-2028)
9.2 Latin America Chorionic Gonadotrophin for Injection Market Size by Application
9.2.1 Latin America Chorionic Gonadotrophin for Injection Sales by Application (2017-2028)
9.2.2 Latin America Chorionic Gonadotrophin for Injection Revenue by Application (2017-2028)
9.3 Latin America Chorionic Gonadotrophin for Injection Market Size by Country
9.3.1 Latin America Chorionic Gonadotrophin for Injection Sales by Country (2017-2028)
9.3.2 Latin America Chorionic Gonadotrophin for Injection Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Chorionic Gonadotrophin for Injection Market Size by Specification
10.1.1 Middle East and Africa Chorionic Gonadotrophin for Injection Sales by Specification (2017-2028)
10.1.2 Middle East and Africa Chorionic Gonadotrophin for Injection Revenue by Specification (2017-2028)
10.2 Middle East and Africa Chorionic Gonadotrophin for Injection Market Size by Application
10.2.1 Middle East and Africa Chorionic Gonadotrophin for Injection Sales by Application (2017-2028)
10.2.2 Middle East and Africa Chorionic Gonadotrophin for Injection Revenue by Application (2017-2028)
10.3 Middle East and Africa Chorionic Gonadotrophin for Injection Market Size by Country
10.3.1 Middle East and Africa Chorionic Gonadotrophin for Injection Sales by Country (2017-2028)
10.3.2 Middle East and Africa Chorionic Gonadotrophin for Injection Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Beijing Science Sun Pharmaceutical
11.1.1 Beijing Science Sun Pharmaceutical Corporation Information
11.1.2 Beijing Science Sun Pharmaceutical Overview
11.1.3 Beijing Science Sun Pharmaceutical Chorionic Gonadotrophin for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Beijing Science Sun Pharmaceutical Chorionic Gonadotrophin for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Beijing Science Sun Pharmaceutical Recent Developments
11.2 Shenyang EverBright Pharmaceutical
11.2.1 Shenyang EverBright Pharmaceutical Corporation Information
11.2.2 Shenyang EverBright Pharmaceutical Overview
11.2.3 Shenyang EverBright Pharmaceutical Chorionic Gonadotrophin for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Shenyang EverBright Pharmaceutical Chorionic Gonadotrophin for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Shenyang EverBright Pharmaceutical Recent Developments
11.3 Yantai Dongcheng Beifang Pharmaceutical
11.3.1 Yantai Dongcheng Beifang Pharmaceutical Corporation Information
11.3.2 Yantai Dongcheng Beifang Pharmaceutical Overview
11.3.3 Yantai Dongcheng Beifang Pharmaceutical Chorionic Gonadotrophin for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Yantai Dongcheng Beifang Pharmaceutical Chorionic Gonadotrophin for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Yantai Dongcheng Beifang Pharmaceutical Recent Developments
11.4 Livzon Pharmaceutical Group
11.4.1 Livzon Pharmaceutical Group Corporation Information
11.4.2 Livzon Pharmaceutical Group Overview
11.4.3 Livzon Pharmaceutical Group Chorionic Gonadotrophin for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Livzon Pharmaceutical Group Chorionic Gonadotrophin for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Livzon Pharmaceutical Group Recent Developments
11.5 Ningbo Renjian Pharmaceutical
11.5.1 Ningbo Renjian Pharmaceutical Corporation Information
11.5.2 Ningbo Renjian Pharmaceutical Overview
11.5.3 Ningbo Renjian Pharmaceutical Chorionic Gonadotrophin for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Ningbo Renjian Pharmaceutical Chorionic Gonadotrophin for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Ningbo Renjian Pharmaceutical Recent Developments
11.6 Ma’anshan Fengyuan Pharmaceutical
11.6.1 Ma’anshan Fengyuan Pharmaceutical Corporation Information
11.6.2 Ma’anshan Fengyuan Pharmaceutical Overview
11.6.3 Ma’anshan Fengyuan Pharmaceutical Chorionic Gonadotrophin for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Ma’anshan Fengyuan Pharmaceutical Chorionic Gonadotrophin for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Ma’anshan Fengyuan Pharmaceutical Recent Developments
11.7 Harbin High-Tech Group Baitian’er Pharmaceutical
11.7.1 Harbin High-Tech Group Baitian’er Pharmaceutical Corporation Information
11.7.2 Harbin High-Tech Group Baitian’er Pharmaceutical Overview
11.7.3 Harbin High-Tech Group Baitian’er Pharmaceutical Chorionic Gonadotrophin for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Harbin High-Tech Group Baitian’er Pharmaceutical Chorionic Gonadotrophin for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Harbin High-Tech Group Baitian’er Pharmaceutical Recent Developments
11.8 Sinopharm
11.8.1 Sinopharm Corporation Information
11.8.2 Sinopharm Overview
11.8.3 Sinopharm Chorionic Gonadotrophin for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Sinopharm Chorionic Gonadotrophin for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Sinopharm Recent Developments
11.9 Besins Healthcare Benelux
11.9.1 Besins Healthcare Benelux Corporation Information
11.9.2 Besins Healthcare Benelux Overview
11.9.3 Besins Healthcare Benelux Chorionic Gonadotrophin for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Besins Healthcare Benelux Chorionic Gonadotrophin for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Besins Healthcare Benelux Recent Developments
11.10 Bristol Myers Squibb
11.10.1 Bristol Myers Squibb Corporation Information
11.10.2 Bristol Myers Squibb Overview
11.10.3 Bristol Myers Squibb Chorionic Gonadotrophin for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Bristol Myers Squibb Chorionic Gonadotrophin for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Bristol Myers Squibb Recent Developments
11.11 Organon
11.11.1 Organon Corporation Information
11.11.2 Organon Overview
11.11.3 Organon Chorionic Gonadotrophin for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Organon Chorionic Gonadotrophin for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Organon Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Chorionic Gonadotrophin for Injection Industry Chain Analysis
12.2 Chorionic Gonadotrophin for Injection Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Chorionic Gonadotrophin for Injection Production Mode & Process
12.4 Chorionic Gonadotrophin for Injection Sales and Marketing
12.4.1 Chorionic Gonadotrophin for Injection Sales Channels
12.4.2 Chorionic Gonadotrophin for Injection Distributors
12.5 Chorionic Gonadotrophin for Injection Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Chorionic Gonadotrophin for Injection Industry Trends
13.2 Chorionic Gonadotrophin for Injection Market Drivers
13.3 Chorionic Gonadotrophin for Injection Market Challenges
13.4 Chorionic Gonadotrophin for Injection Market Restraints
14 Key Findings in The Global Chorionic Gonadotrophin for Injection Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
| 【注射用絨毛性ゴナドトロピンについて】 ※注射用絨毛性ゴナドトロピン（Chorionic Gonadotrophin for Injection）は、主に生殖医療やホルモン療法に使用される薬剤です。この薬剤は、妊娠を維持するためや、排卵を誘発するために用いられます。以下に、その定義、特徴、種類、用途、および関連技術について詳述いたします。 まず、注射用絨毛性ゴナドトロピンとは何かについて説明します。この薬は、ヒトの絨毛組織から抽出されるホルモンで、主成分はヒト絨毛性ゴナドトロピン（hCG）です。hCGは、妊娠初期において胎盤によって分泌され、黄体機能をサポートし、妊娠を維持する役割を果たします。また、hCGは体内で黄体を刺激することで、エストロゲンやプロゲステロンの産生を促進します。このように、hCGは妊娠に深く関与しているホルモンであるため、医療分野でも重要な役割を持っています。 次に、注射用絨毛性ゴナドトロピンの特徴について述べます。まずその投与方法ですが、主に皮下または筋肉内に注射して使用されます。注射後は、比較的短期間で体内に作用し、その効果は数日間持続することがあります。hCGは、比較的高い分子量を持つタンパク質であり、生体内での代謝が行われるため、投与後すぐに血中濃度が上昇し、一定の効果を発揮します。そのため、正確なタイミングでの投与が求められます。 注射用絨毛性ゴナドトロピンにはいくつかの種類があります。その中でも、一般的に使用されるのは、組換えヒト絨毛性ゴナドトロピン（rhCG）と呼ばれるものです。これは、遺伝子組換え技術によって製造され、従来の製品よりも均一性や純度が向上しています。これにより、患者への投与時の安全性が高まり、効果がより確実となります。 注射用絨毛性ゴナドトロピンの主な用途は、妊娠誘発や不妊治療です。具体的には、不妊症の治療において、排卵を促進し、妊娠をサポートするために使用されます。特に、多嚢胞性卵巣症候群（PCOS）や、ホルモン補充療法を行っている患者において、排卵誘発剤と併用することが多いです。また、体外受精（IVF）などの生殖技術においても、卵子の成熟を促進する目的で用いられます。 さらに、hCGは一部の病態においても治療に使用されます。たとえば、男子の性腺機能低下症や、女性の黄体機能不全といった疾患に対しても有効性が示されています。これにより、性ホルモンの分泌を正常化させ、関連する症状の改善を図ることができます。 関連技術について触れると、現代の医療では、hCGの作用をよりよく理解し、効果的に利用するための研究が進められています。例えば、hCGの投与タイミングや用量の最適化、また他のホルモン療法との併用による相乗効果の検討が行われています。さらに、hCGの作用に関する分子メカニズムや、生体内での相互作用についての研究が進行しており、それによって新たな治療法の開発につながる可能性があります。 加えて、hCGはその特性から、スポーツ科学や栄養学の分野でも注目されています。特に、体重管理や筋肉の増強を目的としたプログラムにおいて、一時的な代謝の変化を促す手段として使われることがあります。これは、hCGが食欲を抑制したり、脂肪の代謝を促進したりするとの報告があるためです。ただし、この用途についてはさまざまな議論があり、健康への影響や倫理的観点からの注意が必要です。 総じて、注射用絨毛性ゴナドトロピンは、生殖医療やホルモン治療において重要な役割を果たす薬剤です。その特性を活かした多くの臨床応用があり、今後もさらなる研究と応用が期待されています。しかし、適切な使用と副作用への注意が求められるため、医療従事者との十分な相談が必要です。患者自身がこの薬剤についての理解を深め、適切な選択を行うことが、より良い治療結果につながるでしょう。 |